Jeffrey Curtis, MD, MS, MPH, is a professor of medicine in the Division of Clinical Immunology and Rheumatology at the University of Alabama at Birmingham (UAB). He received a medical degree and a Master of Public Health degree from Oregon Health & Sciences University in Portland, where he subsequently completed a residency in internal medicine. He then pursued a fellowship in rheumatology at UAB. Dr Curtis completed a graduate program in clinical informatics at Stanford University and received a Master of Science degree in epidemiology at the Harvard School of Public Health. He is board certified in both rheumatology and clinical informatics.
Dr Curtis holds the Harbert-Ball Endowed Professorship in Rheumatology and Immunology at UAB. His major research emphasis is on evaluating the safety and comparative effectiveness of medications for rheumatic diseases. Dr Curtis also conducts both investigator-initiated and industry-sponsored clinical trials in rheumatoid arthritis (RA) and psoriatic arthritis (PsA), including large pragmatic trials. He is also the co-director of the UAB Pharmacoepidemiology and Pharmacoeconomics Research unit.
In 2012, Dr Curtis was awarded the Henry Kunkel Young Investigator Award by the American College of Rheumatology (ACR) and was accepted into the American Society for Clinical Investigation in 2016. In 2015, he was appointed as a member to the United States Food and Drug Administration (FDA) Arthritis Advisory Committee. Dr Curtis served on the core expert panel for the ACR’s 2008, 2012, and 2015 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in RA. He was the deputy director for a collaborative project between the FDA, the Agency for Healthcare Research and Quality, and a number of academic centers studying the safety of biologic agents using multiple, pooled national data sources.
Dr Curtis is the co-principal investigator of the mobile health-based, PCORI-funded Patient Powered Research Network “ArthritisPower” registry, focused on RA, psoriasis, PsA, and spondyloarthritis. He is the co-principal investigator of the UAB Coordinating Center of the ACR electronic health record-based registry, Rheumatology Informatics System for Effectiveness.
Dr Curtis also leads the multicenter National Institute of Health (NIH)-funded large pragmatic randomized controlled trial “VERVE” studying the safety and effectiveness of the live herpes zoster vaccine in patients receiving biologic agents. He was appointed a member of the Center for Disease Control (CDC) Advisory Committee on Immunization Practices (ACIP) Herpes Zoster workgroup. Dr Curtis also studies risk factors and outcomes of osteoporosis. He was a member of the ACR’s taskforce to update recommendations for the management of glucocorticoid-induced osteoporosis, and served on the American Society of Bone and Mineral Research (ASBMR) taskforce on atypical subtrochanteric and diaphyseal fractures.
Dr Curtis has authored more than 500 peer-reviewed manuscripts, review articles, and book chapters.